These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 17239273)

  • 1. Parenteral estrogens for prostate cancer: can a new route of administration overcome old toxicities?
    Lycette JL; Bland LB; Garzotto M; Beer TM
    Clin Genitourin Cancer; 2006 Dec; 5(3):198-205. PubMed ID: 17239273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer.
    Scherr DS; Pitts WR
    J Urol; 2003 Nov; 170(5):1703-8. PubMed ID: 14532759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen deprivation therapy: evidence-based management of side effects.
    Ahmadi H; Daneshmand S
    BJU Int; 2013 Apr; 111(4):543-8. PubMed ID: 23351025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer, osteoporosis and fracture risk.
    Allain TJ
    Gerontology; 2006; 52(2):107-10. PubMed ID: 16508318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving the management of patients with prostate cancer receiving long-term androgen deprivation therapy.
    Schulman C; Irani J; Aapro M
    BJU Int; 2012 Jun; 109 Suppl 6():13-21. PubMed ID: 22672121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?
    Grossmann M; Zajac JD
    Clin Endocrinol (Oxf); 2011 Mar; 74(3):289-93. PubMed ID: 21092052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer.
    Freedland SJ; Eastham J; Shore N
    Prostate Cancer Prostatic Dis; 2009; 12(4):333-8. PubMed ID: 19901933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.
    Braga-Basaria M; Dobs AS; Muller DC; Carducci MA; John M; Egan J; Basaria S
    J Clin Oncol; 2006 Aug; 24(24):3979-83. PubMed ID: 16921050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth.
    Basaria S
    J Androl; 2008; 29(5):534-9. PubMed ID: 18567642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues.
    Gomella LG
    BJU Int; 2007 Jan; 99 Suppl 1():25-9; discussion 30. PubMed ID: 17229166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Luteinizing hormone--releasing hormone agonists: a quick reference for prevalence rates of potential adverse effects.
    Walker LM; Tran S; Robinson JW
    Clin Genitourin Cancer; 2013 Dec; 11(4):375-84. PubMed ID: 23891497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Managing complications of androgen deprivation therapy for prostate cancer.
    Holzbeierlein JM
    Urol Clin North Am; 2006 May; 33(2):181-90, vi. PubMed ID: 16631456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monotherapy in advanced prostate cancer: an overview.
    Baltogiannis D; Giannakopoulos X; Charalabopoulos K; Sofikitis N
    Exp Oncol; 2004 Sep; 26(3):185-91. PubMed ID: 15494685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen deprivation therapy in prostate cancer: anticipated side-effects and their management.
    Kim HS; Freedland SJ
    Curr Opin Support Palliat Care; 2010 Sep; 4(3):147-52. PubMed ID: 20592607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer?: a conceptual review.
    Bylow K; Mohile SG; Stadler WM; Dale W
    Cancer; 2007 Dec; 110(12):2604-13. PubMed ID: 17960609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.
    Shahani S; Braga-Basaria M; Basaria S
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2042-9. PubMed ID: 18349064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic and cardiovascular effects of androgen deprivation therapy.
    Hakimian P; Blute M; Kashanian J; Chan S; Silver D; Shabsigh R
    BJU Int; 2008 Dec; 102(11):1509-14. PubMed ID: 18727614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
    Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ
    Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.